Literature DB >> 10759767

Effects of anti-rheumatic gold salts on NF-kappa B mobilization and tumour necrosis factor-alpha (TNF-alpha)-induced neutrophil-dependent cytotoxicity for human endothelial cells.

J Bratt1, J Belcher, G M Vercellotti, J Palmblad.   

Abstract

We have previously shown that the gold-containing disease-modifying anti-rheumatic drugs, auranofin (AF) and gold sodium aurothiomalate (GSTM) reduce human umbilical vein endothelial cell (HUVEC) adhesion molecule expression and neutrophil (PMN) adherence. AF diminishes E-selectin and intercellular adhesion molecule-1 (ICAM-1) on cytokine-activated HUVEC, while GSTM decreases only E-selectin. Since tight adhesion is critical for PMN to damage EC, we tested whether these drugs modulated human PMN-mediated injury to TNF-alpha-activated HUVEC in vitro (as measured by 51Cr release). Here we show that TNF-alpha caused a prominent PMN-mediated cytotoxicity that was dose-dependently reduced when AF and GSTM were added to the assay system. We also found that a potent inhibitor of NF-kappaB, pyrrolidine dithiocarbamate (PDTC) in a dose-dependent manner impaired TNF-alpha-induced cytotoxicity, indicating a role of NF-kappaB activation in cytokine-induced endothelial injury. To examine the effects of AF and GSTM on TNF-alpha-induced NF-kappaB activation this was measured in HUVEC nuclear extracts by an electrophoretic mobility shift assay. AF, but not GSTM, decreased TNF-alpha-induced NF-kappaB activation in HUVEC. Thus, in this in vitro model of vasculitis, AF and GSTM dose dependently reduced TNF-alpha-mediated neutrophil-dependent cytotoxicity for HUVEC, and AF, but not GSTM, inhibited NF-kappaB mobilization, thereby providing possible mechanisms for effects of AF and GSTM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759767      PMCID: PMC1905616          DOI: 10.1046/j.1365-2249.2000.01190.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1.

Authors:  M M Corkill; B W Kirkham; D O Haskard; C Barbatis; T Gibson; G S Panayi
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

2.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

3.  Inhibitory effects of gold sodium thiomalate on the proliferation and interferon-gamma induced HLA-DR expression in human endothelial cells.

Authors:  A Kawakami; K Eguchi; K Migita; H Nakao; T Otsubo; Y Ueki; C Shimomura; H Tezuka; M Matsunaga; T Ishimaru
Journal:  J Rheumatol       Date:  1990-04       Impact factor: 4.666

4.  Effects of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress.

Authors:  D Moellering; J McAndrew; H Jo; V M Darley-Usmar
Journal:  Free Radic Biol Med       Date:  1999-05       Impact factor: 7.376

Review 5.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

6.  The effect of slow-acting anti-rheumatic drugs (SAARDs) and combinations of SAARDs on monokine production in vitro.

Authors:  V A Danis; G M Franic; P M Brooks
Journal:  Drugs Exp Clin Res       Date:  1991

7.  Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli.

Authors:  I Hafström; B E Seligmann; M M Friedman; J I Gallin
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Stimulus-specific neutrophil aggregation: evaluation of possible mechanisms for the stimulus-response apparatus.

Authors:  B Ringertz; J Palmblad; J A Lindgren
Journal:  J Lab Clin Med       Date:  1985-08

10.  Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils.

Authors:  P A Detmers; S K Lo; E Olsen-Egbert; A Walz; M Baggiolini; Z A Cohn
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

2.  Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.

Authors:  Hyung S Youn; Joo Y Lee; Shin I Saitoh; Kensuke Miyake; Daniel H Hwang
Journal:  Biochem Biophys Res Commun       Date:  2006-09-28       Impact factor: 3.575

Review 3.  Protein kinase Cι expression and oncogenic signaling mechanisms in cancer.

Authors:  Nicole R Murray; Krishna R Kalari; Alan P Fields
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

Review 4.  Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.

Authors:  Alan P Fields; Roderick P Regala
Journal:  Pharmacol Res       Date:  2007-05-05       Impact factor: 7.658

5.  Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Authors:  Aaron S Mansfield; Alan P Fields; Aminah Jatoi; Yingwei Qi; Alex A Adjei; Charles Erlichman; Julian R Molina
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248

6.  The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma.

Authors:  C Q Ma; Y Yang; J M Wang; G S Du; Q Shen; Y Liu; J Zhang; J L Hu; P Zhu; W P Qi; Y W Qian; Y Fu
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.